• 1
    Yuen M-F, Cheng C-C, Lauder IJ, Lam S-K, Ooi C-G, Lai C-L. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000; 31: 3305.
  • 2
    Dohmen K, Shirahama M, Miyamoto Y, Torii Y, Irie K, Ishibashi H. Differences in survival based on the type of follow-up for the detection of hepatocellular carcinoma: an analysis of 547 patients. Hepatol. Res. 2000; 18: 11021.
  • 3
    Dohmen K, Shigematsu H, Irie K, Ishibash H. Trends in clinical characteristics, treatment and prognosis of hepatocellular carcinoma. Hepatogastroenterology 2003; 50: 18727.
  • 4
    Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J. Hepatol. 2001; 35: 42130.
  • 5
    Pugh RNH, Murray-Lyon IM, Dawson JR, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 1973; 60: 6469.
  • 6
    Okuda K, Ohtsuki T, Obata H et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: Study of 850 patients. Cancer 1985; 56: 91828.
  • 7
    International Union Against Cancer (UICC). In: Sobin LH, Wittekind CH, eds. TNM Classification of Malignant Tumours, 5th edn. New York: Wiley-Liss, 1997; 747.
  • 8
    Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N. Engl. J. Med. 1996; 334: 6939.
  • 9
    Marsh JW, Dvorchik I, Bonham CA, Iwatsuki S. Is the pathologic TNM staging system for patients with hepatoma predictive of outcome? Cancer 2000; 88: 53843.
  • 10
    Llovet JM, Bruix J, Fuster J et al. Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology 1998; 27: 15727.
  • 11
    Izumi R, Shimizu K, Ii T et al. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology 1994; 106: 7207.
  • 12
    Dohmen K, Shigematsu H, Irie K, Ishibashi H. Longer survival in female than male with hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2003; 18: 26772.
  • 13
    The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a prospective study of 435 patients. Hepatology 1998; 28: 7515.
  • 14
    Chevret S, Trinchet J-C, Mathieu D et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. J. Hepatol. 1999; 31: 13341.
  • 15
    Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC Staging Classification. Semin. Liver Dis. 1999; 19: 32938.
  • 16
    Leung TWT, Tang AMY, Zee B et al. Construction of the Chinese University prognostic index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian program staging system. A study based on 926 patients. Cancer 2002; 94: 17609.
  • 17
    Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J. Gastroenterol. 2003; 38: 20715.
  • 18
    Liver Cancer Study Group of Japan. The General Rules for the Clinical and Pathological Study of Primary Liver Cancer, 4th edn. Tokyo: Kanehara, 2000 (in Japanese).
  • 19
    Stillwagon GB, Order SE, Guse C et al. Prognostic factors in unresectable hepatocellular cancer. Radiation Therapy Oncology Group Study 83–01. Int. J. Radiat. Oncol. Biol. Phys. 1991; 20: 6571.
  • 20
    Levy I, Sherman M, Liver Cancer Study Group of the University of Toronto. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging system in a cohort of 257 patients in Toronto. Gut 2002; 50: 8815.
  • 21
    Farinati F, Rinaldi M, Gianni S, Naccarato R. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer 2000; 89: 226673.
  • 22
    Ueno S, Tanabe G, Sako K et al. Discrimination value of the new Western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Hepatology 2001; 34: 52934.
  • 23
    Kawakita T, Shiraki K, Yamanaka Y et al. A new prognostic scoring system involving des-γ-carboxy prothrombin as a useful marker for predicting prognosis in patients with hepatocellular carcinoma. Int. J. Oncol. 2003; 23: 111520.
  • 24
    Omagari K, Honda S, Kadokawa Y et al. Preliminary analysis of a newly proposed scoring system (SliDe score) for hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2004; 19: 80511.
  • 25
    Kuromatsu R, Tanaka M, Shimauchi Y et al. Usefulness of ED036 kit for measuring serum PIVKA-II levels in small hepatocellular carcinoma. J. Gastroenterol. 1997; 32: 50712.
  • 26
    Okuda H, Nakanishi T, Takatsu K et al. Serum levels of des-γ-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma. Cancer 2000; 88: 5449.
  • 27
    Hamamura K, Shiratori Y, Shiina S et al. Unique characteristics of patients with hepatocellular carcinoma who present with high plasma des-γ-carboxy prothrombin and low serum α-fetoprotein. Cancer 2000; 88: 155764.
  • 28
    Dohmen K, Shigematsu H, Irie K, Ishibashi H. Clinical characteristics among patients with hepatocellular carcinoma according to the serum levels of α-fetoprotein and des-γ-carboxy prothrombin. Hepatogastroenterology 2003; 50: 20728.
  • 29
    Koike Y, Shiratori Y, Sato S et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001; 91: 5619.
  • 30
    Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, Ter Borg PCJ. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 86471.
  • 31
    Kamath PS, Wiesner RH, Malinchoc M et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 46470.
  • 32
    Schepke M, Roth F, Fimmers R et al. Comparison of MELD, Child-Pugh, and Emory Model for the prediction of survival in patients undergoing transjugular intrahepatic portosystemic shunting. Am. J. Gastroenterol. 2003; 98: 116774.
    Direct Link:
  • 33
    Salerno F, Merli M, Cazzaniga M et al. MELD score is better than Child-Pugh score in predicting 3-month survival of patients undergoing transjugular intrahepatic portosystemic shunt. J. Hepatol. 2002; 36: 494500.
  • 34
    Inayoshi J, Ichida T, Sugitani S et al. Gross appearance of hepatocellular carcinoma reflects E-cadherin expression and risk of early recurrence after surgical treatment. J. Gastroenterol. Hepatol. 2003; 18: 6737.
  • 35
    Dupuy E, Hainaud P, Villemain A et al. Tumoral angiogenesis and tissue factor expression during hepatocellular carcinoma progression in a transgenic mouse model. J. Hepatol. 2003; 38: 793802.
  • 36
    Yoshida K, Nakamura H, Okuda Y et al. Expression of hepatoma-derived growth factor in hepatocarcinogenesis. J. Gastroenterol. Hepatol. 2003; 18: 1293301.
  • 37
    Armengol C, Boix L, Bachs O et al. P27Kip1 is an independent predictor of recurrence after surgical resection in patients with small hepatocellular carcinoma. J. Hepatol. 2003; 38: 5917.
  • 38
    Fausto N, Laird AD, Webber EM. Liver regeneration 2. Role of growth factors and cytokines in hepatic regeneration. FASEB J. 1995; 9: 152736.
  • 39
    Di Bisceglie AM, Strasberg S. A common staging system for hepatocellular carcinoma. Hepatology 2004; 39: 5501.
  • 40
    Bruix J, Llovet JM. Prognostic prediction in HCC. Did anybody expect it to be easy? Hepatology 2004; 39: 5512.
  • 41
    Colombo M, Sangiovanni A. The strategic role of staging in the treatment of HCC. Hepatology 2004; 39: 5523.